Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Lipidomic profiling of CE and TG species was performed by mass spectrometry-based analysis
The most frequently reported adverse events (AEs) of GLP-1 RAs were gastrointestinal adverse drug reactions, including nausea, vomiting, and abdominal pain, which were closely related to activation of central and peripheral GLP-1 receptors ( In a recent network meta-analysis, overall GLP-1 RAs significantly increased the incidence of gastrointestinal AEs compared with placebo or conventional treatment, and the odds ratios for nausea, vomiting and diarrhea from GLP-1 RAs were 11.8 (95% CI, 2.8946.9), 51.7 (95% CI, 7.07415), and 4.93 (95% CI, 1.7514.7), respectively ( Methods Data sources This retrospective pharmacovigilance study was conducted based on the FDA Adverse Event Reporting System (FAERS) database
In the early stage, GLP-1 drugs had a short half-life in vivo, requiring frequent injections with poor patient compliance
Othal J, Folbergrov J, Kovacs R, Kunz WS, Maggio N (2014) Epileptic focus and alteration of metabolism
US$ 23.37
US$ 26.77
US$ 26.01
